EP2167064A2 - Zusammensetzungen und verfahren zur behandlung von fettsucht und verwandten erkrankungen - Google Patents

Zusammensetzungen und verfahren zur behandlung von fettsucht und verwandten erkrankungen

Info

Publication number
EP2167064A2
EP2167064A2 EP08767455A EP08767455A EP2167064A2 EP 2167064 A2 EP2167064 A2 EP 2167064A2 EP 08767455 A EP08767455 A EP 08767455A EP 08767455 A EP08767455 A EP 08767455A EP 2167064 A2 EP2167064 A2 EP 2167064A2
Authority
EP
European Patent Office
Prior art keywords
agent
pharmaceutical agent
composition
pharmaceutical
phentermine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08767455A
Other languages
English (en)
French (fr)
Inventor
Thomas Najarian
Peter Y. Tam
Leland F. Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivus LLC
Original Assignee
Vivus LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivus LLC filed Critical Vivus LLC
Publication of EP2167064A2 publication Critical patent/EP2167064A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the invention relates generally to pharmaceutical compositions and methods for the treatment of various conditions, disorders, and diseases, and more particularly relates to the treatment of such conditions, disorders, and diseases using therapeutic agents that in combination provide advantages relative to the administration of either agent in a monotherapeutic regimen.
  • the methods and compositions of the invention are particularly useful in the treatment of obesity and related conditions.
  • EV7E1DE3111US display similar side effect profiles, meaning that patients either have to forego therapy or suffer from unpleasant side effects associated with a particular medication.
  • combination treatment may be employed to decrease the doses of the individual components in the resulting combinations while still preventing unwanted or harmful side effects of the individual components.
  • combination treatment offers a choice of various drugs for treating obesity or a related condition.
  • another combination may be administered which will be effective for treating obesity or a related condition.
  • suitable methods for the treatment of obesity and related conditions including combination treatments that result in reduction of toxicity, decreased side effects and effective.
  • the present invention is directed to the use of pharmaceutical agent combinations in which the side effects associated with one or both of the agents administered are reduced.
  • directly reducing side effects is meant that a first pharmaceutical agent allows the second agent to be administered at a lower dose without compromising therapeutic efficacy, thus resulting dose-dependent unwanted effects.
  • conditions of particular interest that may be treated according to the present methodology include obesity and related conditions such as those often associated and/or caused by obesity.
  • the medical problems caused by overweight and obesity can be serious and often life- threatening and include diabetes, shortness of breath and other respiratory problems, gallbladder disease, hypertension, dyslipidemia (for example, high cholesterol or high levels of triglycerides), cancer, osteoarthritis, other orthopedic problems, reflux esophagitis (heartburn), snoring, sleep apnea, menstrual irregularities, infertility, gout, problems associated with pregnancy, heart trouble, muscular dystrophy and metabolic disorders, including hypoalphalipoproteinemia, familial combined hyperlipidemia, insulin resistant syndrome X or multiple metabolic disorder, coronary artery disease, and dyslipidemic hypertension.
  • dyslipidemia for example, high cholesterol or high levels of triglycerides
  • cancer for example, high cholesterol or high levels of triglycerides
  • osteoarthritis other orthopedic problems
  • reflux esophagitis heartburn
  • snoring sleep apnea
  • sleep apnea menstrual irregularities
  • obesity has been associated with an increased incidence of certain cancers, notably cancers of the colon, rectum, prostate, breast, uterus, and cervix.
  • cancers notably cancers of the colon, rectum, prostate, breast, uterus, and cervix.
  • patients who are obese or overweight have a substantially increase risk of morbidity from hypertension, dyslipidemia, type 2 diabetes, coronary heart disease, stroke, gallbladder disease, osteoarthritis and endometrial, breast, prostate, and colon cancers.
  • Higher body weights are also associated with increases in all-cause mortality. Most or all of these problems are relieved or improved by permanent significant weight loss as well as a significant increase in longevity.
  • the currently available strategies for treating these disorders include dietary restriction, increments in physical activity, pharmacological and surgical approaches which vary depending, at least in part, on the degree of weight loss one is attempting to achieve in a subject as well as on the severity of overweight or obesity exhibited by the subject.
  • treatments such as low-fat diet and/or regular exercise are often adequate in cases where a subject is only mildly overweight.
  • over-the-counter appetite suppressants including caffeine, ephedrine and phenylpropanolamine (Acutrim®, Dexatrim®).
  • prescription medications including amphetamine, diethylpropion (Tenuate®), mazindol (Mazanor®, Sanorex®), phentermine (Fastin®, Ionamin®), phenmetrazine (Preludin®), phendimetrazine (Bontrol®, Plegine®, Adipost®, Dital®, Dyrexan®, Melfiat®, Prelu-2®, Rexigen Forte®), benzphetamine (Didrex®) and fluoxetine (Prozac®) are often used in the treatment of seriously overweight and/or obese subjects or patients. However, such treatments, at best, result in only 5-10% weight loss (when accompanied with diet and exercise).
  • fenfluramine is a potent releaser of serotonin from serotonergic neurons which acts on a cerebral appetite center.
  • fenfluramine had the effect of enhancing and extending the anorexient action of phentermine.
  • FDA Food and Drug Administration
  • phentermine in combination with an anti-depressant agent is a potentially effective therapy for effecting weight loss (U.S. Patent No. 5,795,895).
  • the anti-depressants suggested for use in this new combination therapy are members of a class of compounds known as selective serotonin reuptake inhibitors (SSRIs) which include fluoxetine (Prozac ® ), sertraline (Zoloft ® ), fluvoxamine maleate (Luvox ® ) and trazodone hydrochloride (Desyrel ® ).
  • SSRIs selective serotonin reuptake inhibitors
  • the combination therapy is also suggested to treat coexisting depression and/or obsessive-compulsive disorder.
  • Phentermine has also recently been tested in combination with bupropion (Wellbutrin ® ) for the treatment of obesity.
  • Bupropion is an antidepressant that inhibits dopamine reuptake, as compared to serotonin uptake. It is also used to treat attention deficit disorders such as Attention Deficit Hyperactivity Disorder (ADHD), bipolar depression, chronic fatigue syndrome, cocaine addiction, nicotine addiction, and lower back pain.
  • ADHD Attention Deficit Hyperactivity Disorder
  • Zonisamide (ZONEGRANTM), a sulfonamide antiepileptic drug, is used to control some kinds of seizures in the treatment of epilepsy. Zonisamide may produce these effects through action at sodium and calcium channels.
  • zonisamide blocks sodium channels and reduces voltage-dependent, transient inward currents (T-type Ca 2+ currents), consequently stabilizing neuronal membranes and suppressing neuronal hypersynchronization.
  • T-type Ca 2+ currents voltage-dependent, transient inward currents
  • zonisamide binds to the GABA/benzodiazepine receptor ionophore complex in an allosteric fashion which does not produce changes in chloride flux.
  • Other in vitro studies have demonstrated that zonisamide (10-30 ⁇ g/mL) suppresses synaptically-driven electrical activity without affecting postsynaptic GABA or glutamate responses (cultured mouse spinal cord neurons) or neuronal or glial uptake of [ 3 H]-GABA (rat hippocampal slices).
  • zonisamide does not appear to potentiate the synaptic activity of GABA.
  • zonisamide facilitates both dopaminergic and serotonergic neurotransmission.
  • Zonisamide also has weak carbonic anhydrase inhibiting activity, but this pharmacologic effect is not thought to be a major contributing factor in the antiseizure activity of zonisamide.
  • Side effects of zonisamide include but are not limited to: renal calculi, drowsiness, ataxia, loss of appetite, gastrointestinal symptoms, severe rash (i.e. Stevens Johnson Syndrome [SJS] and toxic epidermal necrolysis [TEN]), serious hematologic events, such as aplastic anemia or agranuclocytosis, oligohydrosis and hyperthermia in pediatric patients.
  • topiramate is effective in the treatment of diabetes (U.S. Patent Nos. 7,109,174 and 6,362,220), neurological disorders (U.S. Patent No. 6,908,902), depression (U.S. Patent No. 6,627,653), psychosis (U.S. Patent No. 6,620,819), headaches (U.S. Patent No. 6,319,903) and hypertension (U.S. Patent No. 6,201,010).
  • diabetes U.S. Patent Nos. 7,109,174 and 6,362,220
  • neurological disorders U.S. Patent No. 6,908,902
  • depression U.S. Patent No. 6,627,
  • CBl receptor antagonists may be used in the treatment of obesity. Recent studies have demonstrated that activation of CBl receptors by endogenous cannabinoids, such as anadamide, may cause increases in appetite. Therefore, CBl antagonists or inverse agonists are currently under investigation for controlling appetite in treating obese or overweight patients.
  • rimonabant is a CBl cannabinoid receptor antagonist which causes a significant reduction in appetite.
  • the medication causes, among other effects, decrease in appetite, possible increase in metabolic activity, and blockage of lipogenesis. See, e.g., despres et al. (2005) NEJM 353: 2121-34.
  • rimonabant did not enter the market in the United States because the FDA required additional information pertaining to associations between rimonabant and increased rates of psychiatric adverse events, including depression and suicidality and neurological adverse events, including seizures.
  • FDA MEMORANDUM from Division of Metabolism and Endocrinology Products (May 22, 2007)
  • CBl antagonists for the treatment of obesity has been hindered by concomitant side effects such as sedation and depression of the CNS.
  • a potential treatment for obesity is marred by the negative effects a patient would need to endure in order to lose weight — a major problem for patient compliance and for the patient's health.
  • the invention is directed to compositions and methods wherein two or more therapeutic agents are used in combination and administered for the treatment of obesity and related conditions.
  • the invention involves administering a combination of therapeutic agents wherein a second agent directly or indirectly reduces the unwanted side effects resulting from administration of the first agent.
  • a prolonged dosage regimen e.g., involving daily or weekly dosing for a period of weeks or even months or years.
  • the drug combinations of the present invention provide a choice of various drugs for an individual who does not react to one particular combination or experiences adverse side effects.
  • a second combination of drugs may be administered to an individual when a first drug combination was not effective for treating obesity or a related condition.
  • the present invention features a novel therapy for treating obesity and related conditions, including conditions associated with and/or caused by obesity per se.
  • the method involves treating a subject with a first pharmaceutical agent and a second pharmaceutical agent, wherein the second pharmaceutical agent is a sympathomimetic agent.
  • sympathomimetic agent is a term of art and refers to agents or compounds which mimic or alter stimulation of the sympathetic nervous system.
  • the present invention is directed towards a composition for treating obesity or a related condition in a subject which includes a first pharmaceutical agent and a second pharmaceutical agent, wherein the second pharmaceutical agent is a sympathomimetic agent and wherein the first pharmaceutical agent is an anti-epileptic agent,
  • CB 1 receptor antagonist or a 5HT 2 c-selective serotonin receptor agonist.
  • the sympathomimetic agent is phentermine or bupropion.
  • the first pharmaceutical agent is an anti-epileptic agent.
  • the anti-epileptic agent is selected from the group consisting of topiramate, zonisamide, ⁇ -vinyl GABA (vigabatrin), carbamazepine, clonazepam, ethosuximide, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, primidone, tiagabine, valproate, felbamate, oxazinane-dione, metharbital, ethotoin and mesantoin, vigabatrin, gabapentin, and oxcarbazepine.
  • the anti-epileptic agent is topiramate.
  • the anti-epileptic agent is zonisamide.
  • the first pharmaceutical agent is a CB 1 receptor antagonist.
  • CBl receptor antagonist is selected from the group consisting of rimonabant, SLV-326, SLV-319, AM251, AM4113, AM281, Taranabant, NIDA-41020, NEWW 0327, O-2050, O-2654, CP-272871, CP-945598, CP-946598, AVE1625, Surinabant, LY320135, AVN-342, GRC-10389, Org-50189, PSNCBAM-I, E-6776, V- 24343, ACPA, ACEA, HU-210, and HU-243.
  • the CBl receptor antagonist is rimonabant.
  • the first pharmaceutical agent is a 5HT 2 c-selective serotonin receptor agonist.
  • the 5HT 2 c-selective serotonin receptor agonist is selected from the group consisting of lorcaserin, mesulergine, agomelatine, fluoxetine, BVT933, DPCA37215, 1K264; PNU 22394; WAY161503, R-1065, and YM 348.
  • the 5HT 2 c-selective serotonin receptor agonist is lorcaserin.
  • the present invention is directed to a dosage form of a pharmaceutical composition comprising a combination of an immediate release form of the sympathomimetic agent and a controlled release form of the anti-epileptic agent, CBl receptor antagonist, or 5HT 2 c-selective serotonin receptor agonist.
  • the dosage form comprises an immediate release form of phentermine while in other aspects, the dosage form comprises an immediate release form of bupropion.
  • the dosage form comprises a controlled release form of an anti- epileptic agent.
  • the anti-epileptic agent is topiramate, while in other aspects, the anti-epileptic agent is zonisamide.
  • the dosage form comprises a controlled release form of the CBl receptor antagonist.
  • the CBl receptor antagonist is rimonabant.
  • the dosage form comprises a controlled release form of the 5HT 2 c-selective serotonin receptor agonist.
  • the 5HT 2 c-selective serotonin receptor agonist is lorcaserin.
  • the present invention is directed towards a method for treating obesity or a related condition in a subject comprising administering to the subject a first pharmaceutical agent and a second pharmaceutical agent, wherein the second pharmaceutical agent is a sympathomimetic agent and wherein the first pharmaceutical agent is an anti-epileptic agent, CBl receptor antagonist, or a 5HT 2 c-selective serotonin receptor agonist.
  • the method includes administering the first pharmaceutical agent and the second pharmaceutical agent separately.
  • the method includes administering the first pharmaceutical agent and the second pharmaceutical agent at different times of the day.
  • the method includes administering the second pharmaceutical agent in the morning and administering the first pharmaceutical agent at least once later in the day.
  • the related condition is pre-diabetes, insulin-resistance or diabetes.
  • the related condition is hypertension.
  • the related condition is sleep apnea.
  • the related condition is nonalcoholic steatohepatitis.
  • the related condition is nonalcoholic fatty liver disease.
  • the related condition is diabetic nephropathy.
  • the present invention is directed towards a kit comprising a packaged combination of a first pharmaceutical agent and a second pharmaceutical agent, wherein the second pharmaceutical agent is a sympathomimetic agent and wherein the first pharmaceutical agent is an anti-epileptic agent, CBl receptor antagonist, or a 5HT 2 c- selective serotonin receptor agonist and instructions for a patient to carry out drug administration to achieve weight loss, wherein the first and second pharmaceutical agents are present in separate and discrete dosage forms.
  • the present invention is directed towards a kit comprising a sealed package of controlled release dosage forms each containing a first pharmaceutical agent and a second pharmaceutical agent, wherein the second pharmaceutical agent is a sympathomimetic agent and wherein the first pharmaceutical agent is an anti-epileptic agent,
  • the dosage forms provide for immediate release of the second pharmaceutical agent and delayed release of the first pharmaceutical agent.
  • the present invention also features a pharmaceutical composition that includes, e.g., bupropion in combination with an anti-epileptic agent, a CBl antagonist, or a 5HT 2 c- selective serotonin receptor agonist.
  • the present invention additionally features a pharmaceutical composition that includes, e.g., phentermine in combination with an anti- epileptic agent, a CBl antagonist, or a 5HT 2 c-selective serotonin receptor agonist.
  • the pharmaceutical composition contains topiramate or zonisamide or rimonabant in combination with phentermine or bupropion.
  • the present invention also features a pharmaceutical composition that includes topirimate in combination with phentermine for treating obesity or a related condition.
  • the present invention also features a pharmaceutical composition that includes zonisamide in combination with phentermine for treating obesity or a related condition.
  • the present invention also features a pharmaceutical composition that includes rimonabant in combination with phentermine for treating obesity or a related condition.
  • the present invention also features a pharmaceutical composition that includes lorcaserin in combination with phentermine for treating obesity or a related condition.
  • the present invention also features a pharmaceutical composition that includes topirimate in combination with bupropion for treating obesity or a related condition.
  • the present invention also features a pharmaceutical composition that includes zonisamide in combination with bupropion for treating obesity or a related condition. [00057] The present invention also features a pharmaceutical composition that includes rimonabant in combination with bupropion for treating obesity or a related condition. [00058] The present invention also features a pharmaceutical composition that includes lorcaserin in combination with bupropion for treating obesity or a related condition.
  • an active agent refers not only to a single active agent but also to a combination of two or more different active agents
  • a dosage form refers to a combination of dosage forms as well as to a single dosage form, and the like.
  • all technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which the invention pertains. Although any methods and materials similar or equivalent to those described herein may be useful in the practice or testing of the present invention, preferred methods and materials are described below. Specific terminology of particular importance to the description of the present invention is defined below.
  • active agent When referring to an active agent, applicants intend the term "active agent" to encompass not only the specified molecular entity but also its pharmaceutically acceptable, pharmacologically active analogs, including, but not limited to, salts, esters, amides, prodrugs, conjugates, active metabolites, and other such derivatives, analogs, and related compounds.
  • treating and “treatment” as used herein refer to reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, prevention of the occurrence of symptoms and/or their underlying cause, and improvement or remediation of damage.
  • treating a patient as described herein encompasses treating obesity or a related condition in an individual.
  • dosage form denotes any form of a pharmaceutical composition that contains an amount of active agent sufficient to achieve a therapeutic effect with a single administration.
  • the dosage form is usually one such tablet or capsule.
  • the frequency of administration that will provide the most effective results in an efficient manner without overdosing will vary with the characteristics of the particular active agent, including both its pharmacological characteristics and its physical characteristics, such as hydrophilicity.
  • controlled release refers to a drug-containing formulation or fraction thereof in which release of the drug is not immediate, i.e., with a “controlled release” formulation, administration does not result in immediate release of the drug into an absorption pool.
  • controlled release includes sustained release and delayed release formulations.
  • sustained release (synonymous with “extended release”) is used in its conventional sense to refer to a drug formulation that provides for gradual release of a drug over an extended period of time, and that preferably, although not necessarily, results in substantially constant blood levels of a drug over an extended time period.
  • delayed release is also used in its conventional sense, to refer to a drug formulation which, following administration to a patient, provides a measurable time delay before drug is released from the formulation into the patient's body.
  • pharmaceutically acceptable is meant a material that is not biologically or otherwise undesirable, i.e., the material may be incorporated into a pharmaceutical composition administered to a patient without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained.
  • pharmaceutically acceptable refers to a pharmaceutical carrier or excipient, it is implied that the carrier or excipient has met the required standards of toxicological and manufacturing testing or that it is included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug administration.
  • “Pharmacologically active” refers to a derivative or analog having the same type of pharmacological activity as the parent compound and approximately equivalent in degree.
  • pharmaceutically acceptable salts include acid addition salts which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like.
  • Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
  • inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
  • the instant invention provides for the pharmaceutical treatment of many conditions, disorders, and diseases wherein side effects are significantly reduced.
  • the invention provides for the treatment of obesity and related conditions associated with and/or caused by obesity, e.g., diabetes, hypertension, and sleep apnea, depression.
  • the subject invention involves treating a subject with a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an anti-epileptic agent, CBl receptor antagonist or a 5HT 2 c-selective serotonin receptor agonist and the second pharmaceutical agent is a sympathomimetic agent.
  • each reduces the side effects of the other agent and both contribute to the pharmacology effect of enhancing weight loss. Because they both enhance weight loss, one can reduce the dose of each component to make the combination more tolerable.
  • Sympathomimetic agents for use in the present invention and their general clinical uses or effects are set forth in Table I.
  • the ⁇ and ⁇ in the prototype formula refer to positions of the C atoms in the ethylamine side chain.
  • the sympathomimetic agent is phentermine or a phentermine-like compound.
  • a phentermine-like compound is a compound structurally related to phentermine (e.g., an analog or derivative) which maintains an anorectic activity similar to that of phentermine.
  • One phentermine-like compound is chlorphentermine.
  • the sympathomimetic agent is amphetamine or an amphetamine-like compound.
  • an amphetamine-like compound is a compound structurally related to amphetamine (e.g., an analog or derivative) which maintains an anorectic effect of amphetamine.
  • the sympathomimetic agent is phenmetrazine or a phenmetrazine-like compound.
  • a phenmetrazine-like compound is a compound structurally related to phenmetrazine (e.g., an analog or derivative) which maintains an anorectic effect of phenmetrazine.
  • One phenmetrazine-like compound is phendimetrazine.
  • Analogs and/or derivatives of the compounds of the present invention can be tested for their ability to suppress appetite (e.g., suppress food intake) in a subject (e.g., a mammalian subject).
  • the sympathomimetic agent is bupropion or a bupropion- like compound.
  • a bupropion-like compound is a compound structurally related to bupropion (e.g. , an analog or derivative) which maintains an anti-depressive activity similar to that of bupropion.
  • the sympathomimetic agent is selected from bupropion, amphetamine, methamphetamine, benzphetamine, phenylpropanolamine, phentermine, chlorphentermine, diethylpropion, phenmetrazine, and phendimetrazine (as set forth in Table I).
  • the sympathomimetic agent is phentermine.
  • the first pharmaceutical agent is an anti- epileptic agent which are generally imidazoles (such as imidazole per se), imidazole derivatives, sulfonamides (such as topiramate), and sulfonylureas (such as zonisamide).
  • anti-epileptic agents include GABA-T inhibitors like ⁇ -vinyl GABA (vigabatrin).
  • Anti- epileptic agents include carbamazepine, clonazepam, ethosuximide, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, primidone, tiagabine, topiramate, valproate, felbamate, oxazinane-dione, metharbital, ethotoin and mesantoin, vigabatrin, gabapentin, and oxcarbazepine.
  • Antiepileptic agents also include anticonvulsant sulfamate compounds and anticonvulsant sulfonylurea compounds as further defined below.
  • anticonvulsant sulfamate compound (s), anticonvulsant sulfamate agent(s) anticonvulsant sulfamate derivative(s) or anticonvulsant sulfamate drug(s) are terms of art and refer to a class of sulfamate-derived compounds that possess anticonvulsant activity and have an art-recognized use in the treatment of epilepsy.
  • the anticonvulsant sulfamate compounds are monosaccharide derivatives with sulfamate functionality.
  • the anticonvulsant sulfamate compounds for use in the present invention have one or more of the following modes of activity: modulation of voltage-dependent sodium conductance; potentiation of gamma-am inobutyric acid-evoked currents; inhibition of the kainate/alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) subtype of the glutamate receptor; and/or inhibition of carbonic anhydrase (e.g., a mechanism by which the anticonvulsant derivative of the present invention may decrease the sensation of taste).
  • AMPA kainate/alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid
  • carbonic anhydrase e.g., a mechanism by which the anticonvulsant derivative of the present invention may decrease the sensation of taste.
  • the anticonvulsant sulfamate compound is a compound having the following formula (I):
  • X is CH 2 or O
  • Ri is H or alkyl
  • R 2 , R 3 , R 4 and R 5 are independently H or lower alkyl, with the proviso that when X is O, then R 2 and R 3 and/or R 4 and R 5 together may be a methylenedioxy group of the following formula (II):
  • R ⁇ and R 7 are the same or different and are H or lower alkyl, or are joined to form a cyclopentyl or cyclohexyl ring.
  • R) in particular is hydrogen or alkyl of about 1 to 4 carbons, such as methyl, ethyl, or isopropyl.
  • Alkyl includes both straight and branched chain alkyl.
  • Alkyl groups R 2 , R 3 , R 4 , R 5 , Re and R 7 are about 1 to 3 carbons and include methyl, ethyl, isopropyl and n-propyl.
  • a particular group of compounds of the formula (I) are those wherein X is oxygen and both R 2 and R 3 , and R 4 and R5 together are methylenedioxy groups of the formula (II), wherein R 6 and R 7 are both hydrogen, both alkyl, or combine to form a spiro cyclopentyl or cyclohexyl ring, in particular, where R 6 and R 7 are both alkyl such as methyl.
  • a second group of compounds are those wherein X is CH 2 and R 4 and R5 are joined to form a benzene ring.
  • a third group of compounds of the formula (I) are those wherein both R 2 and R 3 are hydrogen.
  • the anticonvulsant sulfamate compound is topiramate (Topamax ® ).
  • Topiramate also referred to in the art as 2,3:4,5-bis-O-(l-methylethylidene)- ⁇ - D-fructopyranose sulfamate, has been demonstrated in clinical trials of human epilepsy to be effective as an adjunctive therapy or as monotherapy in treating simple and complex partial seizures and secondarily generalized seizures (E. Faught et al (1995) Epilepsia 36(suppl 4):33; S. Sachdeo et al. (1995) Epilepsia 36(suppl 4):33) and is currently marketed for the treatment of simple and complex partial seizure epilepsy with or without secondary generalized seizures.
  • the sulfamate compound is selected from 2,3-O-(l- methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; 2,3-O-(l- methylethylidene)-4,5-O-sulfonyl-beta-L-fructopyranose sulfamate; 2,3-O-(l - methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose methylsulfamate; 2,3-O-(l- methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose butylsulfamate; 2,3-O-(l- methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose butylsulf
  • the anticonvulsant sulfonylurea compound is zonisamide.
  • Zonisamide (ZONEGRANTM), a sulfonylurea antiepileptic drug, is used to control some kinds of seizures in the treatment of epilepsy. Zonisamide may produce these effects through action at sodium and calcium channels.
  • Other sulfonylurea antiepileptic drugs include chlorpropamide, tolazamide, tolbutamide, glyburide, glipizide and glimepiride.
  • the first pharmaceutical agent is a CBl receptor antagonist.
  • CBl receptor antagonist or inverse agonist examples include rimonabant (SR141716A) (known in Europe as Acomplia® and supplied by Sanofi- Aventis); SLV-326, SLV-319 (Solvay); AM251, AM4113 and AM281 (Univ.
  • the CBl antagonist is rimonabant.
  • the first pharmaceutical agent is a serotonin receptor agonist, for example a 5HT 2 c-selective serotonin receptor agonist, that has an anorectic effect.
  • a 5HT 2 c-selective serotonin receptor agonist is lorcaserin (Arena Pharmaceuticals), mesulergine, agomelatine and fluoxetine.
  • Additional 5HT 2 c-selective serotonin receptor agonists which may be used in the instant invention include BVT933, DPCA37215, 1K264; PNU 22394; WAY161503, R-1065, and YM 348.
  • the choice of appropriate dosages for the drugs used in combination therapy according to the present invention can be determined and optimized by the skilled artisan, e.g., by observation of the patient, including the patient's overall health, the response to the combination therapy, and the like. Optimization, for example, may be necessary if it is determined that a patient is not exhibiting the desired therapeutic effect or conversely, if the patient is experiencing undesirable or adverse side effects that are too many in number or are of a troublesome severity.
  • each component of the combination e.g., (i) a sympathomimetic drug, and (ii) an anti-epileptic agent, a CBl receptor antagonist, or a 5HT 2 c-selective serotonin receptor agonist
  • a sympathomimetic drug e.g., a spasmodic drug
  • an anti-epileptic agent e.g., an anti-epileptic agent, a CBl receptor antagonist, or a 5HT 2 c-selective serotonin receptor agonist
  • the components may be prescribed separately or as a combination dosage.
  • each component of the combination e.g., (i) a sympathomimetic drug, and (ii) an anti-epileptic agent, a CBl receptor antagonist, or a 5HT 2 c-selective serotonin receptor agonist
  • a dose that is lower than the typically described dose for each component as a monotherapy The components may be prescribed separately or as a combination dosage.
  • the prescribed dosage of the sympathomimetic drug is above the typically described dose for monotherapy, and the anti-epileptic agent, CBl receptor antagonist, or 5HT 2 c-selective serotonin receptor agonist is prescribed at a dosage that is at or below the typically described dose for monotherapy.
  • the prescribed dosage of the sympathomimetic drug is at or below the typically described dose for monotherapy, and the anti-epileptic agent, CBl receptor antagonist, or 5HT 2 c-selective serotonin receptor agonist is prescribed at a dosage that is above the typically described dose for monotherapy.
  • the sympathomimetic drug or anti-epileptic agent or CBl receptor antagonist or 5HT 2 c-selective serotonin receptor agonist may be administered at a dose ranging from 0.1-500 mg daily, such as from 10-400, and including from 20-400, and including from 50-200, and including from 25-200 mg daily.
  • the sympathomimetic drug or anti-epileptic agent or CBl receptor antagonist or 5HT 2 c-selective serotonin receptor agonist may be administered at a dose ranging from 1-250 mg daily, such as from 1-200, and including from 2-100, and including from 2-60, and including from 2-30 mg daily.
  • the sympathomimetic drug or anti -epileptic agent or CBl receptor atagonist or 5HT 2C -selective serotonin receptor agonist may be administered at a dose ranging from 0.1-100 mg daily, such as from 0.2-50 and including from 0.2-25 and including from 0.25-10 and including from 0.25-5 mg daily.
  • phentermine when phentermine is the sympathomimetic agent, phentermine may be, for example, administered at a dose ranging from 2-60 mg daily. In one aspect, the phentermine is administered at a dose ranging from 2-30 mg daily.
  • bupropion when bupropion is the sympathomimetic agent, bupropion may be, for example, administered at a dose ranging from 50-400 mg daily. In one aspect, the bupropion is administered at a dose ranging from 50-200 mg daily.
  • topiramate when topiramate is the first pharmaceutical agent, topiramate may be administered at a dose ranging from 20-400 mg daily.
  • topiramate is administered at a dose ranging from 25-200 mg daily.
  • zonisamide when zonisamide is the first pharmaceutical agent, zonisamide may be administered at a dose ranging from 20-400 mg daily. In one aspect, zonisamide is administered at a dose ranging from 20-200 mg daily.
  • rimonabant when rimonabant is the first pharmaceutical agent, rimonabant may be administered at dose ranging from 0.25-50 mg daily, such as from 1.0-25 mg daily.
  • rimonabant is administered at dose ranging from 2-15 mg daily, including from 2-10 mg daily, while in other aspects, rimonabant is administered at a dose ranging from 3-7.5 mg daily or from 3-5 mg daily.
  • tiranabant when taranabant is the first pharmaceutical agent, tiranabant may be administered at a dose ranging from 0.25-50 mg daily, such as from 0.25- 10 mg daily.
  • taranabant is administered between 0.25-8 mg daily, including from 0.25- 7 mg daily, while in other aspects, tiranabant is administered at a dose ranging from 0.25-7.5 mg daily or from 0.25-5 mg daily.
  • lorcaserin when lorcaserin is the first pharmaceutical agent, lorcaserin may be administered at a dose ranging from 2-50 mg daily, such as from 2-20 mg daily, including from 5-15 mg daily. In one aspect, lorcaserin is administered at a dose ranging from 2-10 mg daily, including from 3.5-7.5 mg daily.
  • the patient may receive the specific dosage over a period of weeks, months, or years. For example, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years and the like.
  • an "effective amount" of the combination therapy is an amount that results in a reduction of at least one pathological parameter associated with obesity or a related condition.
  • an effective amount of the combination therapy is an amount that is effective to achieve a reduction of at least about 10%, at least about 15%, at least about 20%, or at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95%, compared to the expected reduction in the parameter associated with obesity or a related condition.
  • the sympathomimetic agent and the anti-epileptic agent, CBl antagonist, or 5HT 2 c-selective serotonin receptor agonist may be administered substantially simultaneously (e.g., within about 60 minutes, about 50 minutes, about 40 minutes, about 30 minutes, about 20 minutes, about 10 minutes, about 5 minutes, or about 1 minute of each other) or separated in time by about 1 hour, about 2 hours, about 4 hours, about 6 hours, about 10 hours, about 12 hours, about 24 hours, about 36 hours, or about 72 hours, or more.
  • compositions of the invention in unit dosage form for ease of administration and uniformity of dosage.
  • the specifications of the novel dosage unit forms of the invention are dependent on the unique characteristics of the composition containing the anti-epileptic, CBl antagonist, or 5HT 2 c-selective serotonin receptor agonist and the sympathomimetic agent and the particular therapeutic effect to be achieved. Dosages can further be determined by reference to the usual dose and manner of administration of the ingredients.
  • compositions or combinations of the invention will depend, in particular, on the type of sympathomimetic agent used and the chosen anti- epileptic agent, CBl receptor antagonist, or 5HT 2 c-selective serotonin receptor agonist.
  • the sympathomimetic agent and the anti-epileptic agent, CBl receptor antagonist, or 5HT 2 c- selective serotonin receptor agonist may be administered together in the same composition or simultaneously or sequentially in two separate compositions.
  • one or more sympathomimetic agents or one or more anti-epileptic agents, CBl receptor antagonists, or 5HT 2 c-selective serotonin receptor agonist may be administered to a subject or patient either in the form of a therapeutic composition or in combination, e.g., in the form of one or more separate compositions administered simultaneously or sequentially.
  • the schedule of administration will be dependent on the type of sympathomimetic agent(s) and anti-epileptic agent(s), CBl receptor antagonist(s), or 5HT 2 c-selective serotonin receptor agonist(s) chosen.
  • a sympathomimetic agent can have a stimulant effect and the degree of such stimulant effect may vary depending on the sympathomimetic agent chosen. Accordingly, a sympathomimetic agent having a significant stimulant effect might be administered earlier in the day than administration of a sympathomimetic agent having a lesser stimulant effect.
  • an anti-epileptic agent, CBl receptor antagonist, or 5HT 2 c-selective serotonin receptor agonist can have a sedative effect and the degree of such sedative effect may vary depending on the compound chosen. Accordingly, an anti-epileptic agent, CBl receptor antagonist, or 5HT 2 c-selective serotonin receptor agonist having a significant sedative effect might be administered later in the day than administration of a compound having a lesser sedative effect. Moreover, sympathomimetic agents, anti-epileptic agents, CBl receptor antagonists, or 5HT 2 c-selective serotonin receptor agonists having lesser stimulant or sedative effects, respectively, may be administered simultaneously.
  • topirimate is administered as a controlled release form and phentermine is administered as an immediate release form.
  • the phentermine may be taken in the morning because the drug is a stimulant as well as an appetite suppressant.
  • topiramate may be taken later in the day than the phentermine.
  • the patient takes the topiramate in the afternoon, or just before supper or later in the evening because the drug is sedating.
  • zonisamide is administered as a controlled release form and phentermine is administered as an immediate release form.
  • the phentermine may be taken in the morning because the drug is a stimulant as well as an appetite suppressant.
  • zonisamide may be taken later in the day than the phentermine.
  • the patient takes the zonisamide in the afternoon, or just before supper or later in the evening because the drug is sedating.
  • rimonabant is administered as a controlled release form and phentermine is administered as an immediate release form.
  • the phentermine may be taken in the morning because the drug is a stimulant as well as an appetite suppressant.
  • rimonabant may be taken later in the day than the phentermine.
  • the patient takes the rimonabant in the afternoon, or just before supper or later in the evening because the drug is sedating.
  • lorcaserin is administered as a controlled release form and phentermine is administered as an immediate release form.
  • the phentermine may be taken in the morning because the drug is a stimulant as well as an appetite suppressant.
  • lorcaserin may be taken later in the day than the phentermine.
  • the patient takes the lorcaserin in the afternoon, or just before supper or later in the evening because the drug is sedating.
  • topirimate is administered as a controlled release form and bupropion is administered as an immediate release form.
  • the bupropion may be taken in the morning because the drug is a stimulant as well as an appetite suppressant.
  • topiramate may be taken later in the day than the bupropion.
  • the patient takes the topiramate in the afternoon, or just before supper or later in the evening because the drug is sedating.
  • zonisamide is administered as a controlled release form and bupropion is administered as an immediate release form.
  • the bupropion may be taken in the morning because the drug is a stimulant as well as an appetite suppressant.
  • zonisamide may be taken later in the day than the bupropion.
  • the patient takes the zonisamide in the afternoon, or just before supper or later in the evening because the drug is sedating.
  • rimonabant is administered as a controlled release form and bupropion is administered as an immediate release form.
  • the bupropion may be taken in the morning because the drug is a stimulant as well as an appetite suppressant.
  • rimonabant may be taken later in the day than the bupropion.
  • the patient takes the rimonabant in the afternoon, or just before supper or later in the evening because the drug is sedating.
  • lorcaserin is administered as a controlled release form and bupropion is administered as an immediate release form.
  • the bupropion may be taken in the morning because the drug is a stimulant as well as an appetite suppressant.
  • lorcaserin may be taken later in the day than the bupropion.
  • the patient takes the lorcaserin in the afternoon, or just before supper or later in the evening because the drug is sedating.
  • Administration of the active agent may be carried out using any appropriate mode of administration.
  • administration can be, for example, oral, parenteral, transdermal, transmucosal (including rectal, vaginal, and transurethral), sublingual, by inhalation, or via an implanted reservoir in a dosage form.
  • parenteral as used herein is intended to include subcutaneous, intravenous, and intramuscular injection.
  • the pharmaceutical formulation may be a solid, semi-solid or liquid, such as, for example, a tablet, a capsule, a caplet, a liquid, a suspension, an emulsion, a suppository, granules, pellets, beads, a powder, or the like, preferably in unit dosage form suitable for single administration of a precise dosage.
  • suitable pharmaceutical compositions and dosage forms may be prepared using conventional methods known to those in the field of pharmaceutical formulation and described in the pertinent texts and literature, e.g., in Remington: The Science and Practice of Pharmacy (Easton, PA: Mack Publishing Co., 1995).
  • oral dosage forms are generally preferred, and include tablets, capsules, caplets, solutions, suspensions and syrups, and may also comprise a plurality of granules, beads, powders, or pellets that may or may not be encapsulated.
  • Preferred oral dosage forms are tablets and capsules.
  • compositions of the invention in unit dosage form for ease of administration and uniformity of dosage.
  • unit dosage forms refers to physically discrete units suited as unitary dosages for the individuals to be treated. That is, the compositions are formulated into discrete dosage units each containing a predetermined, "unit dosage” quantity of an active agent calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specifications of unit dosage forms of the invention are dependent on the unique characteristics of the active agent to be delivered. Dosages can further be determined by reference to the usual dose and manner of administration of the ingredients.
  • two or more individual dosage units in combination provide a therapeutically effective amount of the active agent, e.g., two tablets or capsules taken together may provide a therapeutically effective dosage of the first pharmaceutical active agent, e.g., anti-epileptic agent, CBl receptor antagonist, or a 5HT 2 c - selective serotonin receptor agonist or the second pharmaceutical agent, e.g., the sympathomimetic agent, e.g., phentermine or bupropion, such that the unit dosage in each tablet or capsule is approximately 50% of the therapeutically effective amount.
  • Tablets may be manufactured using standard tablet processing procedures and equipment. Direct compression and granulation techniques are preferred.
  • tablets will generally contain inactive, pharmaceutically acceptable carrier materials such as binders, lubricants, disintegrants, fillers, stabilizers, surfactants, coloring agents, and the like.
  • Capsules are also preferred oral dosage forms for those pharmaceutical active agents that are orally active, in which case the active agent-containing composition may be encapsulated in the form of a liquid or solid (including particulates such as granules, beads, powders or pellets).
  • Suitable capsules may be either hard or soft, and are generally made of gelatin, starch, or a cellulosic material, with gelatin capsules preferred.
  • Two-piece hard gelatin capsules are preferably sealed, such as with gelatin bands or the like. See, for example, Remington: The Science and Practice of Pharmacy, cited earlier herein, which describes materials and methods for preparing encapsulated pharmaceuticals.
  • Oral dosage forms may, if desired, be formulated so as to provide for controlled release of the first pharmaceutical active agent, e.g., anti-epileptic agent, CBl receptor antagonist, or a 5HT 2 c -selective serotonin receptor agonist or the second pharmaceutical agent, e.g., the sympathomimetic agent, e.g., phentermine or bupropion, and in a preferred embodiment, the present formulations are controlled release oral dosage forms.
  • the first pharmaceutical active agent e.g., anti-epileptic agent, CBl receptor antagonist, or a 5HT 2 c -selective serotonin receptor agonist
  • the second pharmaceutical agent e.g., the sympathomimetic agent, e.g., phentermine or bupropion
  • the present formulations are controlled release oral dosage forms.
  • the dosage forms provide for sustained release, i.e., gradual, release of the first pharmaceutical active agent, e.g., anti- epileptic agent, CBl receptor antagonist, or a 5HT 2 c -selective serotonin receptor agonist or the second pharmaceutical agent, e.g., the sympathomimetic agent, e.g., phentermine or bupropion, from the dosage form to the patient's body over an extended time period, typically providing for a substantially constant blood level of the agent over a time period in the range of about 4 to about 12 hours, typically in the range of about 6 to about 10 hours.
  • the first pharmaceutical active agent e.g., anti- epileptic agent, CBl receptor antagonist, or a 5HT 2 c -selective serotonin receptor agonist
  • the second pharmaceutical agent e.g., the sympathomimetic agent, e.g., phentermine or bupropion
  • the dosage form containing the first pharmaceutical active agent e.g., anti-epileptic agent, CBl receptor antagonist, or a 5HT 2 c -selective serotonin receptor agonist or the second pharmaceutical agent, e.g., the sympathomimetic agent, e.g., phentermine or bupropion, such that peak blood level is not reached until at least 4-6 hours have elapsed, with the rate of increase of blood level drug approximately linear, e.g., (generally about 50-200 ⁇ g/ml for topiramate, about 1-5 ⁇ g/ml for zonisamide, or about 10- 35 ⁇ g/ml for acetazolamide).
  • the first pharmaceutical active agent e.g., anti-epileptic agent, CBl receptor antagonist, or a 5HT 2 c -selective serotonin receptor agonist
  • the second pharmaceutical agent e.g., the sympathomimetic agent, e.g., phentermine
  • sustained release dosage forms are formulated by dispersing the active agent within a matrix of a gradually hydrolyzable material such as a hydrophilic polymer, or by coating a solid, drug- containing dosage form with such a material.
  • Hydrophilic polymers useful for providing a sustained release coating or matrix include, by way of example: cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose, cellulose acetate, and carboxymethylcellulose sodium; acrylic acid polymers and copolymers, preferably formed from acrylic acid, methacrylic acid, acrylic acid alkyl esters, methacrylic acid alkyl esters, and the like, e.g.
  • Preferred sustained release dosage forms herein are composed of the acrylate and methacrylate copolymers available under the tradename "Eudragit” from Rohm Pharma (Germany).
  • the Eudragit series E, L, S, RL, RS, and NE copolymers are available as solubilized in organic solvent, in an aqueous dispersion, or as a dry powder.
  • Preferred acrylate polymers are copolymers of methacrylic acid and methyl methacrylate, such as the Eudragit L and Eudragit S series polymers.
  • Particularly preferred such copolymers are Eudragit L-30D-55 and Eudragit L- 100-55 (the latter copolymer is a spray-dried form of Eudragit L-30D-55 that can be reconstituted with water).
  • the molecular weight of the Eudragit L-30D-55 and Eudragit L-100-55 copolymer is approximately 135,000 Da, with a ratio of free carboxyl groups to ester groups of approximately 1:1.
  • the copolymer is generally insoluble in aqueous fluids having a pH below 5.5.
  • Another particularly suitable methacrylic acid-methyl methacrylate copolymer is Eudragit S-100, which differs from Eudragit L-30D-55 in that the ratio of free carboxyl groups to ester groups is approximately 1:2.
  • Eudragit S-100 is insoluble at pH below 5.5, but unlike Eudragit L-30D-55, is poorly soluble in aqueous fluids having a pH in the range of 5.5 to 7.0. This copolymer is soluble at pH 7.0 and above.
  • Eudragit L-100 may also be used, which has a pH-dependent solubility profile between that of Eudragit L-30D-55 and Eudragit S-100, insofar as it is insoluble at a pH below 6.0. It will be appreciated by those skilled in the art that Eudragit L-30D-55, L- 100-55, L-100, and S-100 can be replaced with other acceptable polymers having similar pH- dependent solubility characteristics.
  • Eudragit polymers are cationic, such as the Eudragit E, RS, and RL series polymers.
  • Eudragit ElOO and E PO are cationic copolymers of dimethylaminoethyl methacrylate and neutral methacrylates (e.g., methyl methacrylate), while Eudragit RS and Eudragit RL polymers are analogous polymers, composed of neutral methacrylic acid esters and a small proportion of trimethylammonioethyl methacrylate.
  • Preparations according to this invention for parenteral administration include sterile aqueous and nonaqueous solutions, suspensions, and emulsions.
  • Injectable aqueous solutions contain the active agent in water-soluble form.
  • nonaqueous solvents or vehicles include fatty oils, such as olive oil and corn oil, synthetic fatty acid esters, such as ethyl oleate or triglycerides, low molecular weight alcohols such as propylene glycol, synthetic hydrophilic polymers such as polyethylene glycol, liposomes, and the like.
  • Parenteral formulations may also contain adjuvants such as solubilizers, preservatives, wetting agents, emulsif ⁇ ers, dispersants, and stabilizers, and aqueous suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, and dextran.
  • Injectable formulations are rendered sterile by incorporation of a sterilizing agent, filtration through a bacteria-retaining filter, irradiation, or heat. They can also be manufactured using a sterile injectable medium.
  • the active agent may also be in dried, e.g., lyophilized, form that may be rehydrated with a suitable vehicle immediately prior to administration via injection.
  • the active agent may also be administered through the skin using conventional transdermal drug delivery systems, wherein the active agent is contained within a laminated structure that serves as a drug delivery device to be affixed to the skin.
  • the drug composition is contained in a layer, or "reservoir,” underlying an upper backing layer.
  • the laminated structure may contain a single reservoir, or it may contain multiple reservoirs.
  • the reservoir comprises a polymeric matrix of a pharmaceutically acceptable contact adhesive material that serves to affix the system to the skin during drug delivery.
  • the drug-containing reservoir and skin contact adhesive are present as separate and distinct layers, with the adhesive underlying the reservoir which, in this case, may be either a polymeric matrix as described above, or it may be a liquid or hydrogel reservoir, or may take some other form.
  • Transdermal drug delivery systems may in addition contain a skin permeation enhancer.
  • the active agent may be formulated as a depot preparation for controlled release of the active agent, preferably sustained release over an extended time period.
  • sustained release dosage forms are generally administered by implantation (e.g., subcutaneously or intramuscularly or by intramuscular injection).
  • compositions will generally be administered orally, parenterally, transdermally, or via an implanted depot, other modes of administration are suitable as well.
  • administration may be transmucosal, e.g., rectal or vaginal, preferably using a suppository that contains, in addition to the active agent, excipients such as a suppository wax.
  • Transmucosal administration also encompasses transurethral administration, as described, for example, in U.S. Patent Nos. 5,242,391, 5,474,535, and 5,773,020 to Place et al.
  • Formulations for nasal or sublingual administration are also prepared with standard excipients well known in the art.
  • the pharmaceutical compositions of the invention may also be formulated for inhalation, e.g., as a solution in saline, as a dry powder, or as an aerosol.
  • conditions of particular interest include obesity and related conditions, such as those often associated with and/or caused by obesity.
  • an anti-epileptic agent, CB 1 receptor antagonist, or a 5HT 2 c-selective serotonin receptor agonist with one or more sympathomimetic agents such as phentermine and/or bupropion provide increased therapeutic effects, and reduced adverse effects, making these pharmaceutical combinations extremely effective therapeutics, especially in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se.
  • combination treatment may be employed to decrease the doses of the individual components in the resulting combinations while still preventing unwanted or harmful side effects of the individual components.
  • combination treatment offers a choice of various drugs for treating obesity or a related condition.
  • another combination may be administered which will be effective for treating obesity or a related condition.
  • the drug combinations of the present invention provides a choice of various drugs for an individual who does not react to one particular combination or experiences adverse side effects.
  • a second combination of drugs may be administered to an individual when a first drug combination was not effective for treating obesity or a related condition.
  • Subjects suitable for treatment with the subject combination therapy treatment regimen include individuals suffering from the following conditions associated with obesity, including, hypertension, diabetes or glucose intolerance and insulin resistance, hyperlipidemia, and often tiredness and sleepiness associated with sleep apnea. Patients are often treated with combinations of antihypertensives, lipid lowering agents, insulin or oral diabetic drugs, and various mechanical and surgical methods for treating sleep apnea. However, such treatments are often costly and do not treat the underlying problem of obesity. Moreover, some of the treatments for diabetes including insulin and oral diabetic agents actually aggravate the conditions associated with obesity by increasing insulin levels, increasing appetite, and increasing weight. This can lead to higher blood pressure and even higher cholesterol. Overweight and Obesity:
  • Symptoms of overweight and obesity are usually quite obvious, as excess fat is often easy to see on a person, individuals.
  • the medical problems caused by overweight and obesity can be serious and often life-threatening, and include diabetes, shortness of breath and other respiratory problems, gallbladder disease, hypertension, dyslipidemia (for example, high cholesterol or high levels of triglycerides), cancer, osteoarthritis, other orthopedic problems, reflux esophagitis (heartburn), snoring, sleep apnea, menstrual irregularities, infertility and heart trouble.
  • obesity and overweight substantially increase the risk of morbidity from hypertension, dyslipidemia, type 2 diabetes, coronary heart disease, stroke, gallbladder disease, osteoarthritis and endometrial, breast, prostate, and colon cancers. Higher body weights are also associated with increases in all-cause mortality. Most or all of these problems are relieved or improved by permanent significant weight loss. Longevity is likewise significantly increased by permanent significant weight loss. Diabetes:
  • Diabetes mellitus is associated with continuous and pathologically elevated blood glucose concentration. It is one of the leading causes of death in the United States and is responsible for about 5% of all mortality. Diabetes is divided into two major sub-classes: Type I, also known as juvenile diabetes, or Insulin-Dependent Diabetes Mellitus (IDDM); and Type II, also known as adult onset diabetes, or Non-Insulin-Dependent Diabetes Mellitus (NIDDM).
  • IDDM Insulin-Dependent Diabetes Mellitus
  • NIDDM Non-Insulin-Dependent Diabetes Mellitus
  • Type I Diabetes is a form of autoimmune disease. Autoantibodies produced by the patients completely or partially destroy the insulin producing cells of the pancreas. Juvenile diabetics must, therefore, receive exogenous insulin during their lifetime. Without treatment, excessive acidosis, dehydration, kidney damage, and death may result. Even with treatment, complications such as blindness, atherosclerosis, and impotence can occur.
  • Type II diabetics There are more than five million Type II (adult onset) diabetics diagnosed in the United States. Type II disease usually begins during middle age; the exact cause is unknown. In Type II diabetics, rising blood glucose levels after meals do not properly stimulate insulin production by the pancreas. Additionally, peripheral tissues are generally resistant to the effects of insulin. The resulting high blood glucose levels (hyperglycemia) can cause extensive tissue damage. Type II diabetics are often referred to as insulin resistant. They often have higher than normal plasma insulin levels (hyperinsulinemia) as the body attempts to overcome its insulin resistance.
  • hyperinsulinemia may be a causative factor in the development of high blood pressure, high levels of circulating low density lipo-proteins (LDLs), and lower than normal levels of the beneficial high density lipo-proteins (HDLs). While moderate insulin resistance can be compensated for in the early stages of Type II diabetes by increased insulin secretion, in advanced disease states insulin secretion is also impaired.
  • LDLs low density lipo-proteins
  • HDLs beneficial high density lipo-proteins
  • Insulin resistance and hyperinsulinemia have also been linked with two other metabolic disorders that pose considerable health risks: impaired glucose tolerance and metabolic obesity. Impaired glucose tolerance is characterized by normal glucose levels before eating, with a tendency toward elevated levels (hyperglycemia) following a meal. According to the World Health Organization, approximately 11% of the U.S. population between the ages of 20 and 74 are estimated to have impaired glucose tolerance. These individuals are considered to be at higher risk for diabetes and coronary artery disease. In certain aspects, the subject invention may be employed for treating pre-diabetes such that administering the invention to a patient may prevent the onset of diabetes. [000126] Obesity may also be associated with insulin resistance.
  • diabetes A causal linkage among obesity, impaired glucose tolerance, and Type II diabetes has been proposed, but a physiological basis has not yet been established. Some researchers believe that impaired glucose tolerance and diabetes are clinically observed and diagnosed only later in the disease process after a person has developed insulin resistance and hyperinsulinemia. [000127] Insulin resistance is frequently associated with hypertension, coronary artery disease (arteriosclerosis), and lactic acidosis, as well as related disease states. The fundamental relationship between these disease states, and a method of treatment, has not been established. Diabetic nephropathy:
  • Diabetic nephropathy nephropatia diabetica
  • Kimmelstiel- Wilson syndrome and intercapillary glomerulonephritis is a progressive kidney disease caused by angiopathy of capillaries in the kidney glomeruli. It is characterized by nephrotic syndrome and nodular glomerulosclerosis. It is due to longstanding diabetes mellitus, and is a prime cause for dialysis in many Western countries
  • Hypertension [000129] Hypertension is a condition that occurs when the blood pressure inside the large arteries is too high. Hypertension is very common, affecting about 50 million people in the United States alone. It is more common as people grow older and is both more common and more serious in African Americans.
  • hypertension Most cases of hypertension are of unknown etiology. It is known that the tendency to develop hypertension can be inherited. Environment also plays a very important.role in hypertension. For example, hypertension may be avoided by keeping body weight under control, keeping physically fit, eating a healthy diet, limiting alcohol intake, and avoiding medications that might increase blood pressure. Other less common causes of hypertension include disorders of the kidneys or endocrine glands. Hypertension has been called "the silent killer" because it has no specific symptoms and yet can lead to death. People with untreated hypertension are much more likely to die from or be disabled by cardiovascular complications such as strokes, heart attacks, heart failure, heart rhythm irregularities, and kidney failure, than people who have normal blood pressure.
  • adrenergic neuron antagonists which are peripherally acting
  • alpha adrenergic agonists which are centrally acting
  • alpha adrenergic blockers alpha and beta blockers
  • angiotensin II receptor blockers alpha and beta blockers
  • angiotensin converting enzyme (ACE) inhibitors beta adrenergic blockers
  • calcium channel blockers thiazides (benzothiadiazine derivatives) and related diuretics
  • vasodilators which act by direct relaxation of vascular smooth muscles.
  • a particularly serious hypertensive disorder is primary pulmonary hypertension, also known as idiopathic pulmonary hypertension. This is a condition in which the blood pressure in the pulmonary arteries is abnormally high in the absence of other diseases of the heart or lungs. The cause of primary pulmonary hypertension is unknown. Pulmonary hypertension develops in response to increased resistance to blood flow. Narrowing of the pulmonary arterioles occurs and the right side of the heart becomes enlarged due to the increased work of pumping blood against the resistance. Eventually, progressive heart failure develops. Currently, there is no known cure for primary pulmonary hypertension. Treatment is primarily directed towards controlling the symptoms, although some success has occurred with the use of vasodilators.
  • pulmonary hypertension is a progressive disease, usually leading to congestive heart failure and respiratory failure.
  • Secondary pulmonary hypertension is a serious disorder that arises as a complication of other conditions such as, for example, scleroderma. Treatments are similar as those for primary pulmonary hypertension and, unfortunately, the prognosis is the same as well.
  • Sleep apnea occurs in two main types: obstructive sleep apnea, the more common form that occurs when throat muscles relax; and central sleep apnea, which occurs when the brain doesn't send proper signals to the muscles that control breathing. Additionally, some people have mixed sleep apnea, which is a combination of both obstructive and central sleep apneas. Sleep apnea literally means "cessation of breath.” It is characterized by repetitive episodes of upper airway obstruction that occur during sleep, usually associated with a reduction in blood oxygen saturation. In other words, the airway becomes obstructed at several possible sites.
  • the upper airway can be obstructed by excess tissue in the airway, large tonsils, a large tongue and usually includes the airway muscles relaxing and collapsing when asleep. Another site of obstruction can be the nasal passages. Sometimes the structure of the jaw and airway can be a factor in sleep apnea.
  • the signs and symptoms of obstructive and central sleep apneas overlap, sometimes making the type of sleep apnea more difficult to determine.
  • the most common signs and symptoms of obstructive and central sleep apneas include: excessive daytime sleepiness (hypersomnia); loud snoring; observed episodes of breathing cessation during sleep; abrupt awakenings accompanied by shortness of breath; awakening with a dry mouth or sore throat; morning headache; and/or difficulty staying asleep (insomnia).
  • Disruptive snoring may be a more prominent characteristic of obstructive sleep apnea, while awakening with shortness of breath may be more common with central sleep apnea.
  • Sleep apnea is a progressive condition and should not be taken lightly. It is a potentially life-threatening condition that requires immediate medical attention.
  • the risks of undiagnosed obstructive sleep apnea include heart attacks, strokes, impotence, irregular heartbeat, high blood pressure and heart disease.
  • obstructive sleep apnea causes daytime sleepiness that can result in accidents, lost productivity and interpersonal relationship problems. The severity of the symptoms may be mild, moderate or severe.
  • Sleep apnea is diagnosed utilizing a sleep test, called polysomnography but treatment methodologies differ depending on the severity of the disorder. Mild Sleep Apnea is usually treated by some behavioral changes. Losing weight, sleeping on your side are often recommended.
  • There are oral mouth devices that help keep the airway open) that may help to reduce snoring in three different ways. Some devices (1) bring the jaw forward or (2) elevate the soft palate or (3) retain the tongue (from falling back in the airway and blocking breathing).
  • C-PAP continuous positive airway pressure
  • Bi-PAP Bi-level
  • the Bi-level machine is different in that it blows air at two different pressures. When a person inhales, the pressure is higher and in exhaling, the pressure is lower.
  • Some people have facial deformities that may cause the sleep apnea. It simply may be that their jaw is smaller than it should be or they could have a smaller opening at the back of the throat.
  • Epilepsy is defined as a brain disorder with recurrent, unprovoked seizures.
  • Epilepsy includes seizures of focal onset and generalized seizures.
  • the types of focal onset seizures are partial seizures of temporal lobe origin, frontal lobe origin or others.
  • Focal epilepsies with genetic components include benign childhood epilepsy with centrotemporal spikes, childhood epilepsy with occipital paroxysms or primary reading epilepsy.
  • the generalized genetic epilepsies include benign neonatal familial convulsions, benign neonatal convulsions, benign myoclonic epilepsy in infancy, childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, and epilepsy with grand mal seizures on awakening.
  • the cryptogenic childhood epilepsies with generalized seizures include infantile spasms without tuberous sclerosis, West syndrome, Lennox-Gastaut syndrome, epilepsy with myoclonic-astatic seizures, epilepsy with myoclonic absences, and symptomatic epilepsy such as infantile spasms associated with tuberous sclerosis, epilepsy with continuous spike and wave EEG during slow-wave sleep, and acquired epileptic aphasia (Landau-Klef ⁇ her syndrome).
  • convulsive disorders include all forms of epilepsies, for example, temporal lobe epilepsy, focal epilepsies, including idiopathic epilepsies such as benign childhood epilepsy with centrotemporal spikes, childhood epilepsy with occipital paroxysms or primary reading epilepsy, symptomatic epilepsies with simple partial seizures, complex partial seizures, secondarily generalized seizures, generalized epilepsies and syndromes; generalized epilepsies including idiopathic epilepsies such as benign neonatal familial convulsions, benign neonatal convulsions, benign myoclonic epilepsy in infancy, childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, and epilepsy with grand mal seizures on awakening; cryptogenic or symptomatic epilepsies including West syndrome, Lennox-Gastaut syndrome
  • Symptoms associated with, or arising from epilepsy include convulsions, grand mal seizures, absence seizures, petit mal seizures, focal seizures, temporal lobe seizures, psychomotor seizures, muscle spasms, loss of consciousness, strange sensations, strange emotions and strange behavior.
  • Migraines are convulsions, grand mal seizures, absence seizures, petit mal seizures, focal seizures, temporal lobe seizures, psychomotor seizures, muscle spasms, loss of consciousness, strange sensations, strange emotions and strange behavior.
  • migraines are generally headaches that are typically associated with various psychological (e.g., irritability, depression, fatigue, drowsiness, and restlessness), neurological (e.g., photophobia, and phonophobia), and gastrointestinal symptoms.
  • the headache starts with mild pain, which increases in intensity over a short period of time.
  • Symptoms associated with migraines include headaches, psychological symptomatology such as irritability, depression, fatigue, drowsiness, restlessness; neurological symptoms such as photophobia, phonophobia or gastrointestinal symptoms such as change in bowel habit, change of food intake or urinary symptoms such as urinary frequency, auras which are neurological deficits and can be a variety of deficits for the migraine population but in the individual is usually stereotyped. These deficits may be visual scotoma or visual designs, hemiplegia, migrating paraesthesia, dysarthria, dysphasia, or deja-vu.
  • the headache is usually accompanied by light or sound sensitivity, photophobia or phonophobia, irritability and impaired concentration. Depression:
  • Depression is manifested by a combination of symptoms that interfere with the ability to work, study, sleep, eat, and enjoy once pleasurable activities. Depression includes major depression, especially refractory depression, bipolar depression, and the degeneration associated with depression.
  • Symptoms of depression include persistent sad, anxious, or "empty” mood, feelings of hopelessness, pessimism, feelings of guilt, worthlessness, helplessness, loss of interest or pleasure in hobbies and activities that were once enjoyed, including sex, decreased energy, fatigue, being “slowed down”, difficulty concentrating, remembering, making decisions, insomnia, early-morning awakening, or oversleeping, appetite and/or weight loss or overeating and weight gain, thoughts of death or suicide; suicide attempts, restlessness, irritability, persistent physical symptoms that do not respond to treatment, such as headaches, digestive disorders, and chronic pain.
  • Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease includes
  • Nonalcoholic steatohepatitis is a common, often "silent" liver disease. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol.
  • the major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to work properly.
  • NASH affects 2 to 5 percent of Americans. An additional 10 to 20 percent of Americans have fat in their liver, but no inflammation or liver damage, a condition called "fatty liver.” Although having fat in the liver is not normal, by itself it probably causes little harm or permanent damage. If fat is suspected based on blood test results or scans of the liver, this problem is called nonalcoholic fatty liver disease (NAFLD). If a liver biopsy is performed in this case, it will show that some people have NASH while others have simple fatty liver. Others: [000145] Other psychiatric disorders may also be treated using the compositions and methods of the invention. These disorders include panic syndrome, general anxiety disorder, phobic syndromes of all types, mania, manic depressive illness, hypomania, unipolar depression, stress disorders, PTSD, somatoform disorders, personality disorders, psychosis, and schizophrenia.
  • Impulse Control Disorders are characterized by harmful behaviors performed in response to irresistible impulses.
  • the essential feature of an impulse control disorder is the failure to resist an impulse, drive, or temptation to perform an act that is harmful to the person or to others.
  • Symptoms include an increasing sense of tension or arousal before committing an act, and then experiences pleasure, gratification, or release at the time of committing the act. After the act is performed, there may or may not be regret or guilt.
  • impulse control disorders including intermittent explosive disorder, kleptomania, pathological gambling, pyromania, trichotillomania, compulsive buying or shopping, repetitive self-mutilation, nonparaphilic sexual addictions, severe nail biting, compulsive skin picking, personality disorders with impulsive features, attention deficit/hyperactivity disorder, eating disorders characterized by binge eating, and substance use disorders.
  • Alcohol addiction is characterized in a subject by the presence of one or more of the following symptoms.
  • the subject has a tolerance for alcohol.
  • the subject has withdrawal symptoms after stopping drinking alcohol.
  • the subject takes alcohol in larger amounts than was intended.
  • the subject lacks the ability to decrease the amount of alcohol consumed.
  • the subject spends a great deal of time attempting to acquire alcohol.
  • the subject continues to use alcohol even though the subject should know that there are reoccurring physical or psychological problems being caused by the alcohol.
  • Symptoms associated with alcohol addiction include death from alcohol toxemia, cirrhosis of the liver, pancreatitis, heart disease, polyneuropathy, alcoholic dementia, increased incidence of many types of cancer: breast cancer, head and neck cancer, esophageal cancer and colorectal cancer, nutritional deficiency involving deficiencies in folic acid, thiamine (vitamin Bl), sexual dysfunction, osteoporosis and osteonecrosis.
  • KITS KITS:
  • kits for practicing the subject methods may vary greatly in regards to the components included.
  • the subject kits at least include a first pharmaceutical agent and a second pharmaceutical agent, wherein the second pharmaceutical agent is a sympathomimetic agent and wherein the first pharmaceutical agent is an anti- epileptic agent, CBl receptor antagonist, or a 5HT 2 c-selective serotonin receptor agonist.
  • the subject kits include instructions for a patient to carry out drug administration to treat obesity and/or those conditions associated with obesity.
  • the instructions may be recorded on a suitable recording medium or substrate.
  • the instructions may be printed on a substrate, such as paper or plastic, etc.
  • the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or sub-packaging) etc.
  • the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, etc.
  • the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided.
  • An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate
  • kits may be packaged in suitable packaging to maintain sterility.
  • the components of the kit are packaged in a kit containment element to make a single, easily handled unit, where the kit containment element, e.g., box or analogous structure, may or may not be an airtight container, e.g., to further preserve the sterility of some or all of the components of the kit.
  • the subject kit comprises a sealed package of controlled release dosage forms wherein the dosage forms provide for immediate release of the second pharmaceutical agent and delayed release of the first pharmaceutical agent.
  • a combination of Topiramate and Bupropion was administered to a patient seeking to lose weight.
  • Subject 1 A male patient suffering from obesity had a starting body weight of 245 lbs., an initial Body Mass Index (BMI) of 36 and a Baseline Blood Pressure of (BP) 122/60.
  • BMI Body Mass Index
  • BP Baseline Blood Pressure
  • Patient sought treatment for weight loss.
  • Patient was administered a combination of Bupropion and Topiramate according to the following dosing regimen: • 150 mg of Bupropion (slow release) and 25 mg of Topiramate (administered at night) for week 1 ;
  • a first follow-up visit occurred approximately 4.5 weeks after starting treatment.
  • Patient weighed 228 lbs. and had a BP of 116/60.
  • patient weighed 230 lbs and had a BP of 102/70.
  • a patient seeking to lose weight was initially administered a combination of Phentermine and Topiramate.
  • Subject 2 A male patient suffering from obesity had a starting body weight of 226 lbs., an initial BMI of 29 and a BP of 122/90. This patient had a history of hypertension and was currently taking 20 mg of Lotensin daily.
  • Patient was administered the typical starting doses of Phentermine and Topiramate ending with a dose of 15 mg of Phentermine in the morning and 100 mg of Topiramate at night.
  • patient stated that he was unable to maintain the treatment continuously because he was suffering from various side effects, such as erection dysfunction (ED), insomnia, and anxiety.
  • ED erection dysfunction
  • insomnia insomnia
  • a combination of Topiramate and Bupropion was administered to a patient seeking to lose weight.
  • Subject 3 A female patient suffering from obesity had a starting body weight of 284 lbs., an initial BMI of 45 1/2 and a BP of 122/76. This patient also suffered from hypertension, sleep apnea, depression and pulmonary hypertension.
  • Patient was receiving the following baseline medications: 80 mg/day of Lasix, 10 mg/day of Lisinopril, 10 mg/day of Lexapro, 25 mg of Coreg (2x/day), and 0.5 mg of Xanax (3x/day).
  • Patient was administered a combination of Bupropion and Topiramate according to the following dosing regimen:
  • Phentermine was added at 5 mg/day.
  • a patient seeking to lose weight was initially administered a combination of Topiramate and Bupropion.
  • Subject 4 A female patient suffering from obesity had a starting body weight of 222 lbs. and an initial BMI of 33. This patient had a history of obesity, hypertension, elevated lipids and depression. Patient was administered the typical starting does of Phentermine and Topiramate. Patient was also taking the following baseline meds: 50 mg/day of Cozaar, 20 mg of Prozac (2x/day). Over a period of 3 years, patient was unable to maintain the treatment continuously but did reach a weight of 207 lbs. [000164] In a follow up visit, patient started taking Zonisamide, discontinued taking Topiramate and continued to take the Phentermine as before. During another follow up visit, patient weighed 201 lbs., felt less depressed and had a decreased appetite for carbohydrates and sweets.
  • a patient seeking to lose weight was initially administered a combination of Phentermine and Topiramate.
  • Subject 5 A female patient suffering from obesity had a starting body weight of 185 lbs., an initial BMI of 33 and a BP of 140/72. This patient also suffered from hypertension and chronic lymphocytic leukemia (CLL).
  • CLL chronic lymphocytic leukemia
  • Patient was receiving the following baseline medications: 25 mg/day of HCTZ, 10 mg/day of Prempro, and 10 mg/day of Norvasc.
  • Patient was administered an initial therapy of a combination of Phentermine (1/2 of a 37.5 mg tab) and Topiramate, which was dose-escalated to 100 mg/day.
  • the subject combination therapy may be administered, unless otherwise indicated, by conventional therapeutic regimens and the like, which are within the skill of the art. Such techniques are fully explained in the literature. See, for example, JA ⁇ i.2006; 295:761-775.
  • the effect of the combination of rimonabant and phentermine on weight and cardiometabolic risk factors are studied in overweight and obese patients in a 2-year, randomized, double-blind, placebo-controlled trial. Individuals are assessed and pre-screened to assemble an experimental group of subjects which include men and women aged 18 years or older having a body mass index of 30 or greater (for the obesity study) or 27 or greater (for the overweight study including treated or untreated dyslipidemia or hypertension).
  • Initial screening includes a medical history, physical examination, electrocardiography, clinical chemistry, thyroid function, hematology, and urinalysis.
  • Body weight is measured using a calibrated digital or balance scale at screening, biweekly during the run-in period, baseline (randomization), weeks 2 and 4, and then every 4 weeks.
  • Waist circumference is measured using a spring-loaded measuring tape midway between the lower rib and iliac crest and follow the same measurement schedule as body weight.
  • Patients are excluded if they have a body weight fluctuation of more than 5 kg in the previous 3 months; clinically significant cardiac, renal, hepatic, gastrointestinal tract, neuropsychiatric, or endocrine disorders; drug-treated or diagnosed type 1 or type 2 diabetes; use of medications that alter body weight or appetite; a history of substance abuse or current substance abuse; or changes in smoking habits or smoking cessation within the past 6 months.
  • Patients who complete the run-in period are randomly allocated to 1 of 9 double- blind treatment groups: placebo, 5 mg/d of rimonabant alone, 10 mg/d of rimonabant alone, 15 mg/d of rimonabant alone, 20 mg/d of rimonabant alone, 5 mg/d of rimonabant and 15 mg/d of phentermine, 10 mg/d of rimonabant and 15 mg/d of phentermine, 15 mg/d of rimonabant and 15 mg/d of phentermine or 20 mg/d of rimonabant and 15 mg/d of phentermine.
  • rimonabant and phentermine will be as effective in reducing body weight and waist circumference as compared to the rimonabant doses administed alone while also favorably affecting several cardiometabolic risk factors.
  • the combination of 5 mg/d of rimonabant and 15 mg/d of phentermine will be just as effective in reducing body weight and affecting cardiometabolic risk factors as the 20 mg dose of rimonabant alone but will have a reduction in adverse side effects.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
EP08767455A 2007-06-15 2008-04-29 Zusammensetzungen und verfahren zur behandlung von fettsucht und verwandten erkrankungen Withdrawn EP2167064A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/764,116 US20080103179A1 (en) 2006-10-27 2007-06-15 Combination Therapy
PCT/US2008/005549 WO2008153632A2 (en) 2007-06-15 2008-04-29 Compositions and methods for treating obesity and related disorders

Publications (1)

Publication Number Publication Date
EP2167064A2 true EP2167064A2 (de) 2010-03-31

Family

ID=39744861

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08767455A Withdrawn EP2167064A2 (de) 2007-06-15 2008-04-29 Zusammensetzungen und verfahren zur behandlung von fettsucht und verwandten erkrankungen

Country Status (5)

Country Link
US (1) US20080103179A1 (de)
EP (1) EP2167064A2 (de)
AU (1) AU2008262566A1 (de)
CA (1) CA2692042A1 (de)
WO (1) WO2008153632A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
TW201212918A (en) * 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
SG188361A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Non-hygroscopic salts of 5-ht2c agonists
JP6272695B2 (ja) 2010-09-01 2018-01-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形
WO2012030938A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
AU2015268758B2 (en) * 2010-09-01 2017-08-24 Arena Pharmaceuticals, Inc. Modified-release dosage forms of 5-HT2c agonists useful for weight management
CA2808890A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Administration of lorcaserin to individuals with renal impairment
WO2013028909A1 (en) * 2011-08-25 2013-02-28 Sova Pharmaceuticals, Inc. Combination therapy for the treatment of sleep-related breathing disorders
MX363662B (es) 2012-10-08 2019-03-27 Centro De Investig Y De Estudios Avanzados Del I P N Star Métodos para incrementar la sensibilidad a insulina mediante agonistas de receptores serotonérgicos 5-ht2.
JP2015534563A (ja) 2012-10-09 2015-12-03 アリーナ ファーマシューティカルズ， インコーポレイテッド 体重管理の方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
WO2014181357A1 (en) * 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research Novel pyrazole derivatives with silicon incorporation
US10098893B2 (en) * 2013-10-03 2018-10-16 Northwestern University Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457
WO2015088271A1 (en) * 2013-12-12 2015-06-18 Bio-Pharm Solutions, Co., Ltd. Sulfamate derivative compound for use in preventing or treating epilepsy
WO2016025671A2 (en) * 2014-08-14 2016-02-18 Vivus, Inc. Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
CA2996293C (en) 2015-08-21 2023-12-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and systems for measuring growth rate in plant or aquatic animal species
PL4293009T3 (pl) 2015-12-22 2025-10-06 Zogenix International Limited Kompozycje fenfluraminy i sposoby ich wytwarzania
CA3007673A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
IL290727B2 (en) 2016-08-24 2023-12-01 Zogenix International Ltd Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11571397B2 (en) * 2018-05-11 2023-02-07 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
CA3117868A1 (en) 2018-11-19 2020-05-28 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
US11446262B2 (en) 2018-11-29 2022-09-20 Debora Zucco Sassi Yonezawa Siviglia Neuroquiescence—a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination
US10716792B2 (en) 2018-11-29 2020-07-21 Gary Aaron Howard Neuroquiescence—a treatment for neurological and nervous system bioelectrical dysregulation associated with seizures of epilepsy
WO2020212951A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
WO2021226015A1 (en) * 2020-05-04 2021-11-11 Zucco Sassi Yonezawa Siviglia Debora Neuroquiescence - a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
WO2023278597A1 (en) * 2021-06-30 2023-01-05 Apnimed, Inc. (Delaware) 5-ht2c agonists for use in treating conditions associated with central hypoventilation
US12046341B2 (en) 2021-10-05 2024-07-23 Bradford Rabin Methods and systems for electronically adjusting a dosing pattern of a patient undergoing a medical regimen
WO2023101866A1 (en) * 2021-12-01 2023-06-08 Zogenix International Limited Fenfluramine for treatment of conditions associated with spreading depolarization
CA3268504A1 (en) * 2022-09-26 2024-04-04 Rose Res Center Llc A coverall designed for use in a weight gain prevention program.

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122033A1 (en) 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US20050032773A1 (en) 2000-10-04 2005-02-10 Aventis Pharma S.A. Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositons comprising them and their use in the treatment of obesity
WO2006071740A2 (en) 2004-12-23 2006-07-06 Arena Pharmaceuticals, Inc. 5ht2c receptor modulator compositions and methods of use
WO2006124506A2 (en) 2005-05-13 2006-11-23 Abbott Laboratories Combination and use of drugs
US20080005549A1 (en) 2006-06-30 2008-01-03 Haibin Ke Method for Accelerating BIOS Running
US20080012523A1 (en) 2006-05-11 2008-01-17 Kabushiki Kaisha Toshiba Control device for stepping motor
WO2009061436A1 (en) 2007-11-06 2009-05-14 University Of Florida Research Foundation Compound for activating 5-ht2c receptors in combination with an amphetamine compound

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4895845A (en) * 1986-09-15 1990-01-23 Seed John C Method of assisting weight loss
US4792569A (en) * 1987-08-27 1988-12-20 Mcneilab, Inc. Anticonvulsant phenethyl sulfamates
US5273993A (en) * 1989-06-12 1993-12-28 A. H. Robins Company, Incorporated Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
FR2684101B1 (fr) * 1991-11-22 1993-12-31 Adir Cie Nouveaux derives de benzoate d'ethanolamine, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5543405A (en) * 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity
US5498629A (en) * 1993-12-23 1996-03-12 Ortho Pharmaceutical Corporation Anticonvulsant pseudofructopyranose sulfamates
US5753694A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
US6071537A (en) * 1996-06-28 2000-06-06 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating obesity
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
US5795895A (en) * 1997-06-13 1998-08-18 Anchors; J. Michael Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug
US5990418A (en) * 1997-07-29 1999-11-23 International Business Machines Corporation Hermetic CBGA/CCGA structure with thermal paste cooling
AU771388B2 (en) * 1999-01-19 2004-03-18 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating cluster headaches
WO2000050020A2 (en) * 1999-02-24 2000-08-31 University Of Cincinnati Use of sulfamate derivatives for treating impulse control disorders
NZ514811A (en) * 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
MXPA01010221A (es) * 1999-04-08 2002-03-27 Johnson & Johnson Derivados anticonvulsivos utiles para disminuir la presion sanguinea.
US6420369B1 (en) * 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
WO2000076493A1 (en) * 1999-06-14 2000-12-21 Thomas Najarian Combination therapy for effecting weight loss and treating obesity
WO2002003984A2 (en) * 2000-07-07 2002-01-17 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x
US6627653B2 (en) * 2000-08-02 2003-09-30 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
JP2004518718A (ja) * 2000-10-30 2004-06-24 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 抗糖尿病薬および抗痙攣薬を含んで成る併用療法
DK1471871T3 (da) * 2001-02-02 2007-09-17 Ortho Mcneil Pharm Inc Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin
EP2301537A1 (de) * 2002-05-17 2011-03-30 Duke University Zonisamid zur Behandlung von Fettleibigkeit
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
JP2007517901A (ja) * 2004-01-13 2007-07-05 デューク・ユニバーシティー 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
WO2007084290A2 (en) * 2006-01-12 2007-07-26 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and psychotherapeutic and methods of using the same for reversing weight gain

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032773A1 (en) 2000-10-04 2005-02-10 Aventis Pharma S.A. Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositons comprising them and their use in the treatment of obesity
US20040122033A1 (en) 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
WO2006071740A2 (en) 2004-12-23 2006-07-06 Arena Pharmaceuticals, Inc. 5ht2c receptor modulator compositions and methods of use
WO2006124506A2 (en) 2005-05-13 2006-11-23 Abbott Laboratories Combination and use of drugs
US20080012523A1 (en) 2006-05-11 2008-01-17 Kabushiki Kaisha Toshiba Control device for stepping motor
US20080005549A1 (en) 2006-06-30 2008-01-03 Haibin Ke Method for Accelerating BIOS Running
WO2009061436A1 (en) 2007-11-06 2009-05-14 University Of Florida Research Foundation Compound for activating 5-ht2c receptors in combination with an amphetamine compound

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BRAY GEORGE A.; GREENWAY FRANK L.: "Pharmacological treatment of the overweight patient", PHARMACOLOGICAL REVIEWS, vol. 59, no. 2, 1 June 2007 (2007-06-01), WILLIAMS AND WILKINS INC., BALTIMORE, MD, US, pages 151 - 184, XP002530393
GADDE ET AL: "A 24 week randomised controlled trial of VI-0521, a combination weight loss therapy, in obese adults", OBESITY, vol. 14, no. ABSTR. 55-OR, 2006, pages A17 - A18, XP003026210
GADDE K.M.; ALLISON D.B.: "Cannabinoid-1 Receptor Antagonist,Rimonabant, for Management of Obesity and Related Risks", CIRCULATION, vol. 114, 2006, pages 974 - 984, XP003026208
GADDE KISHORE M. ET AL: "Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study", JOURNAL OF CLINICAL PSYCHIATRY, vol. 68, no. 8, 1 August 2007 (2007-08-01), PHYSICIANS POSTGRADUATE PRESS, INC, US, pages 1226 - 1229, XP009106096
GREENWAY ET AL: "Bupropion and zonisamide for the treatment of obesity", OBESITY, vol. 14, no. ABSTR. 52-OR, 2006, pages A17, XP003026211
INTERNET ARTICLE: "VIVUS, Qnexa Phase 2 Study Results Demonstrate signifacant Weight Loss and Reduction in Waist Circumference", MEDICAL NEWS TODAY, 24 October 2006 (2006-10-24), XP003026209, Retrieved from the Internet <URL:http://www.medicalnewstoday.com/articles/54851.php.>
KAPLAN L.M.: "PHARMACOLOGICAL THERAPIES FOR OBESITY", GASTROENTEROLOGY CLINICS OF NORTH AMERICA, vol. 34, no. 1, 1 March 2005 (2005-03-01), pages 91 - 104, XP009050705
O'NEIL M.J. ET AL: "The Merck Index, 13th edition, No. 8559", 2001, MERCK & CO., INC., WHITEHOUSE STATION, NJ, article "Sibutramine", pages: 1522, XP003026212

Also Published As

Publication number Publication date
CA2692042A1 (en) 2008-12-18
WO2008153632A2 (en) 2008-12-18
AU2008262566A1 (en) 2008-12-18
US20080103179A1 (en) 2008-05-01
WO2008153632A3 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
US20080255093A1 (en) Compositions and methods for treating obesity and related disorders
WO2008153632A2 (en) Compositions and methods for treating obesity and related disorders
US20230233521A1 (en) Escalating dosing regimen for effecting weight loss and treating obesity
US20230225981A1 (en) Low dose topiramate/phentermine composition and methods of use thereof
AU2016203698B2 (en) Low Dose Topiramate/Phentermine Composition and Methods of Use Thereof
AU2016203699A1 (en) Escalating Dosing Regimen for Effecting Weight Loss and Treating Obesity
AU2014202143A1 (en) Low Dose Topiramate / Phentermine Composition and Methods of Use Thereof
AU2014202124A1 (en) Escalating Dosing Regimen for Effecting Weight Loss and Treating Obesity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100115

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20110427

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110908